Our management team is comprised of experienced executives with long track records of success in the development of pharmaceuticals, biotechnology drugs and medical devices.
David Hung, M.D.
Founder, President and Chief Executive Officer
Dr. Hung founded Nuvation Bio in 2018 and serves as President and Chief Executive Officer and member of the Board of Directors.
Dr. Hung founded Medivation, Inc., in 2003, raising a total of $433 million in public offerings over the life of the company to reach a market cap of more than $14 billion, providing investors with a return on investment of 21,000%. In 2016, Medivation was sold to Pfizer for $14.3 billion in an all-cash deal, one of the largest biopharma sales ever by a founding Chief Executive Officer. For his role in creating Medivation, Dr. Hung was named the Life Sciences category winner and Overall U.S. winner across all categories of the 2014 Ernst & Young Entrepreneur of the Year Award.
Dr. Hung identified, in-licensed and led bench-to-bedside development of enzalutamide (XTANDI®) for advanced prostate cancer. At Medivation, XTANDI was taken from first in vitro laboratory experiment to FDA approval in seven years, one of the fastest development timelines in pharmaceutical history. XTANDI, approved in 60+ countries, reached blockbuster drug status, exceeding $3.7 billion in global annual sales in 2019.
At Medivation, Dr. Hung identified, in-licensed and developed talazoparib, a potentially best-in-class PARP inhibitor, which was approved by the FDA in October 2018, and the immune-oncology agent, pidilizumab, which demonstrated robust effects in Phase 2 studies and is now a promising Phase 3-ready asset.
Between Medivation and founding Nuvation Bio, Dr. Hung served for 10 months as Chief Executive Officer at Axovant Sciences before tendering his resignation. Prior to founding Medivation, he served as President and Chief Executive Officer of ProDuct Health, Inc., a venture-backed startup medical device company founded in 1998 that developed, manufactured and commercialized a breast microcatheter – that he invented – for breast cancer risk assessment. ProDuct Health was acquired in 2001 for $168 million by Cytyc Corporation.
Dr. Hung received an A.B. summa cum laude in biology from Harvard College and an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine. He completed simultaneous clinical fellowships in hematology, oncology and transfusion medicine as well as two basic science research fellowships in molecular biology at the University of California, San Francisco, School of Medicine.
SVP, Regulatory Affairs
Dr. DeLuca joined Nuvation Bio in 2021 and has over 25 years of experience in Regulatory Affairs at both large pharma and small biotech companies. Prior to Nuvation, Dr. DeLuca led the regulatory team at Radius Health, which focused in the oncology and osteoporosis therapeutic areas. Her career is hallmarked by multiple product registrations and approvals, and her experience spans the drug development spectrum from pre-IND to post-approval and life cycle management. She is passionate about bringing safer, more effective oncology drugs to cancer patients, and has spent the majority of her regulatory career in the oncology therapeutic area. Dr. DeLuca holds undergraduate and master’s degrees in biology from Eastern Michigan University, earned her PhD from the University of Toledo, and was a postdoctoral fellow at the University of Michigan.
Chief Financial Officer
Ms. Fox joined Nuvation Bio in 2020. She has more than 25 years of experience in healthcare investment banking and has been a lead adviser to life sciences companies on over 125 financing and strategic transactions. she joined the company from Citigroup, where she most recently served as a managing director and Co-Head of North America Healthcare Corporate and Investment Banking Group. Prior to CitiGroup, Ms. Fox held senior positions in investment banking at Deutsche Bank, Bear Stearns, Bank of America and Prudential Securities. She holds B.S. degrees in finance and marketing from Manhattan College.
Gary Hattersley, Ph.D.
Chief Scientific Officer
Dr. Hattersley joined Nuvation Bio in 2019 following a 15-year career at Radius Health Inc, where he supported the development of its oncology and women’s health portfolio, including TYMLOS®, approved by the FDA in 2017 for the treatment of postmenopausal women with osteoporosis at high risk of fracture. At Radius Health, Dr. Hattersley held roles of increasing seniority, including Chief Scientific Officer, Senior Vice President of Preclinical Development, and Vice President of Biology. Prior to Radius Health, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals, where he had responsibility for the discovery and development of novel small molecule agents for the treatment of metabolic bone diseases. He also held positions at Genetics Institute investigating the application of the bone morphogenetic proteins in musculoskeletal disease. Dr. Hattersley received a Ph.D. from St. George’s Hospital Medical School in London.
Senior Vice President of Human Resources
Ms. Markel joined Nuvation Bio in 2019. Previously, she served as Executive Vice President, Human Resources, at Rigel Pharmaceuticals, working collaboratively with the CEO and Executive Committee to support the successful evolution of the company from R&D to commercial stage. Prior to that role, Ms. Markel served as Senior Vice President of Human Resources at Portola Pharmaceuticals, Inc., where she helped successfully transition the company from a development-stage company to a commercial-stage company, preparing the organization for the launch of its first marketed product. Prior to Portola, Ms. Markel served as Senior Vice President of Human Resources and Professional Development at Actelion Pharmaceuticals, Ltd., where she was a member of the Executive Leadership Team and Global Human Resources Leadership Team. She was instrumental in the growth of the organization and in positioning culture as a key advantage in attracting and retaining talent. Ms. Markel has over 25 years of business experience in the pharmaceutical/biotechnology industry. She began her career in sales and sales management with Roche Laboratories. Ms. Markel earned a Bachelor’s degree from the University of California, Davis.
Thomas Templeman, Ph.D.
Senior Vice President of Pharmaceutical Operations and Quality
Dr. Templeman joined Nuvation Bio in 2019 and has more than 25 years of experience in diagnostic and pharmaceutical manufacturing, biopharmaceutical process development, and implementation of quality systems. He previously served as Chief Operating Officer of Greybug Vision and Senior Vice President, Pharmaceutical Operations and Quality Assurance, at Axovant Sciences. Earlier in his career, Dr. Templeman served as Senior Vice President of Pharmaceutical Operations and Quality at Medivation, Vice President of Manufacturing Science and Technology at Hospira, Senior Vice President, Integrated Supply Chain at Liquidia Technologies, and in various leadership roles at Johnson & Johnson, where he worked for 13 years in a number of capacities. Dr. Templeman earned a B.S. in biology from the University of Santa Clara, a Ph.D. in biological sciences from Dartmouth College, and was a post-doctoral fellow at Harvard University. He also obtained Six Sigma Black Belt Certification while at Johnson & Johnson.
Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Dr. Yurasov joined Nuvation Bio in 2019. He is a board-certified, U.S.-licensed hematologist/oncologist with more than 20 years of experience in immunology and oncology. Prior to Nuvation, Dr. Yurasov served as Senior Vice President of Clinical Development and Chief Medical Officer at Immune Design (acquired by Merck in April 2019), where he oversaw clinical, regulatory, pharmacovigilance and medical affairs. Previously, he served as Senior Vice President of Clinical Development at Clovis Oncology, where he oversaw all clinical activities for its rociletinib, rucaparib and lucitanib programs, as well as regulatory approval and launch support for rociletinib and rucaparib. Prior to Clovis, Dr. Yurasov served as Associate Vice President, Global Medicine Science, at ImClone Systems, a subsidiary of Eli Lilly & Co., where he led the development of ramucirumab, which culminated in a FDA submission for an indication in second-line non-small cell lung cancer.
He also served at Hoffman-La Roche as Clinical Director of Oncology, Pharma Research and Early Development. Prior to his industry experience, Dr. Yurasov was Assistant Professor of Clinical Investigation at Rockefeller University, where he was the principal investigator for NIH-funded translational immunology research, and Clinical Instructor in the Department of Pediatrics at Memorial Sloan-Kettering Cancer Center, where he was an attending physician. Dr. Yurasov received an M.D. from the Russian State Medical University and a Ph.D. in medical sciences from the Research Institute for Pediatric Oncology in Moscow. He completed his residency in general pediatrics at Albert Einstein College of Medicine/Jacobi Medical Center and his subspecialty training in pediatric hematology/oncology at Memorial Sloan-Kettering Cancer Center while serving as a research fellow at The Rockefeller University.